Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers

Claud Grigg, Zoë Blake, Robyn Gartrell, Adrian Sacher, Bret Taback, Yvonne Saenger

Research output: Contribution to journalReview articlepeer-review

38 Scopus citations

Abstract

Talimogene laherparepvec (T-Vec) is the first live virus to be approved by the US Food and Drug Administration for the treatment of cancer. This engineered version of herpes simplex virus type 1 (HSV-1) is the product of decades of preclinical work aimed at identifying and modifying aspects of the viral genome involved in virulence and immunogenicity. T-Vec preferentially infects and lyses tumor cells and, in some cases, induces a systemic immune response against the tumor. These properties have translated into significant and durable clinical responses, particularly in advanced melanoma. Many unanswered questions remain, including how to augment these clinical responses and which other tumor types may respond to oncolytic therapy. Here, we review the development of T-Vec, our current understanding of its impact on the tumor immune micro-environment, and its safety and efficacy in clinical trials for melanoma and other cancers.

Original languageEnglish (US)
Pages (from-to)638-646
Number of pages9
JournalSeminars in oncology
Volume43
Issue number6
DOIs
StatePublished - Dec 1 2016
Externally publishedYes

Keywords

  • HSV-1
  • Immunotherapy
  • Melanoma
  • Oncolytic virus
  • T-Vec

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers'. Together they form a unique fingerprint.

Cite this